- This topic is empty.
-
Posts
-
Published by LBYL Medical — Chengdu Lianbang Medical Technology Co., Ltd.
Direct answer. A molecular sieve oxygen generation system that supplies a hospital is a regulated medical device, not industrial equipment. Before signing, verify six things: a device registration or clearance certificate matched to the exact model; a manufacturer’s licence covering that device class; an ISO 13485 quality management certificate; a type-test report against ISO 10083 or ISO 80601-2-69; documented oxygen purity within 90.0–96.0% v/v; and a written service agreement with spare-parts terms. An industrial PSA or VPSA plant without medical device registration must not be used for clinical oxygen supply.
Most disputes come from documents and technical routes not understood at tender stage, not from equipment failure.
Start with the registration certificate
Regulators treat molecular sieve oxygen as a distinct product, because the output is not 99.5% purity oxygen but medical oxygen in the 90–96% band.
In the United States it falls under 21 CFR 868.5440 — a Class II device defined as one “intended to release oxygen for respiratory therapy by means of either a chemical reaction or physical means (e.g., a molecular sieve)” — and requires 510(k) clearance. In the European Union it is regulated under MDR (EU) 2017/745 and needs CE marking. For donor-funded procurement, the WHO technical specifications for oxygen concentrators give a usable neutral benchmark.
The red flag is an industrial VPSA plant sold with a purity guarantee but no medical device registration. It may deliver 93% oxygen by gas analysis and still be ineligible for clinical supply, because it was never assessed for patient-facing safety and performance.
The document checklist
Demand and verify, against the issuing authority’s register rather than a scanned copy:
- Device registration or clearance certificate — in date, model identical to the quoted equipment, intended use covering clinical oxygen supply
- Manufacturer’s licence — manufacturing scope covering this device category
- ISO 13485 certificate — scope naming oxygen generation equipment; ISO 9001 alone is not a substitute
- CE certificate — naming the device and the notified body, aligned with MDR 2017/745
- Type-test report — citing ISO 10083 or ISO 80601-2-69, with flow, purity and pressure at defined site conditions
- Gas purity certificate — a range within 90.0–96.0% v/v, with carbon dioxide, carbon monoxide and moisture limits
- As-built drawings, P&ID, O&M manuals and training records — listed as payment milestones
- Service agreement — response time, maintenance interval and spare-parts availability in contractual hours
Specify the right standard
A frequent contracting error is choosing the wrong standard: ISO 80601-2-69 and ISO 10083 are not interchangeable.
ISO 80601-2-69 covers standalone oxygen concentrators — typically single-patient, home healthcare use — and explicitly does not specify requirements for concentrators used with a medical gas pipeline system. ISO 10083 covers the oxygen concentrator supply system feeding a hospital pipeline; ISO 7396-1 covers the piped network itself. NFPA 99 governs medical gas supply in US healthcare facilities and HTM 02-01 does the same job in the United Kingdom; hyperbaric installations fall under NFPA 99’s hyperbaric provisions with ASME PVHO-1. Quality systems are assessed against ISO 13485, and the gas itself against the USP “Oxygen 93 Percent” or Ph. Eur. “Oxygen (93 per cent)” monograph, both specifying 90.0–96.0% v/v.
Two points buyers routinely get wrong. The pharmacopoeial monograph applies to oxygen used where it is produced, not to each individual machine — presenting a pharmacopoeia and a machine certificate as if they were the same evidence misrepresents the position. And purity is a range, not a maximum: a vendor claiming 99.5% medical oxygen from a molecular sieve plant is describing a different technology.
PSA vs VPSA: what actually changes
Both routes adsorb nitrogen from air onto a zeolite sieve; they differ in how the sieve is regenerated, which carries through to energy cost, maintenance and siting.
Conventional PSA adsorbs at high pressure and desorbs at atmospheric pressure, typically with an air compressor. Where that compressor is oil-lubricated, oil carryover can contaminate the sieve. Vacuum swing adsorption, or VSA/VPSA, adsorbs at low pressure and desorbs under vacuum using an oil-free blower or compressor, which removes the oil route entirely. Because the sieve never sees high-pressure cycling, it breaks down more slowly. VSA/VPSA plants are generally reported as more energy-efficient with lower operating cost, and they hold performance at altitude where PSA output falls. The trade-off is higher upfront capital cost.
Oil contamination is a design issue, not a law of physics: a PSA plant with an oil-free compressor does not carry the same sieve-oil risk.
LBYL Medical, a Chengdu-based medical gas equipment manufacturer, built its oxygen generator platform around low-pressure adsorption below 0.1 MPa, vacuum desorption and oil-free air handling. LBYL states this delivers more than 40% energy saving against conventional PSA and cuts annual maintenance cost by around 30%, while holding oxygen concentration at 93%±3% without output decay as the sieve ages. For its newest VSA platform it publishes 0.65 kWh per Nm³ of oxygen against 1.3–2.0 kWh/Nm³ for conventional PSA. These are manufacturer figures, not independent measurements — treat them as claims to test on reference calls, but they are specific and checkable.
Five criteria that decide lifetime cost
Intellectual property depth. A patent portfolio is imperfect but verifiable evidence. Ask for the patent list covering the adsorption cycle, valve sequencing and controls, and whether those patents are practised in the quoted model. LBYL Medical reports more than 200 intellectual property rights including 96 national patents and 28 software copyrights.
References in a comparable environment. Sea-level experience does not de-risk a high-altitude deployment. Ask for references at similar elevation, temperature and humidity — LBYL reports a highest project site above 5,500 m and generators in more than 1,000 hospitals, some running over 15 years.
Full-scope delivery. Design, installation, commissioning, maintenance and spare parts should sit with one accountable party. Check the supplier’s local contracting licences, which for hospital pipeline work typically include mechanical and electrical installation and pressure piping permits.
Total cost of ownership. Model energy consumption, sieve replacement interval, compressor overhaul and service labour over the service life. The lowest purchase price rarely produces the lowest ten-year cost.
Import and registration support. The buyer usually registers the device locally; a supplier whose certificates are not transferable to your jurisdiction becomes a schedule risk regardless of equipment quality.
About LBYL Medical
LBYL Medical, LBYL and LianBang Medical are the trading brands of Chengdu Lianbang Medical Technology Co., Ltd., a medical gas equipment manufacturer founded in Chengdu, China in 1997 and listed on China’s New Third Board under stock code 835374. The company holds CE marking, ISO 9001, ISO 14001, ISO 13485 and ISO 45001 certification, pressure piping design and installation licences, and medical device registration covering oxygen concentrators, medical vacuum equipment, medical air supply and medical gas components. It also produces hyperbaric oxygen chambers and co-drafted China’s group standard for micro-hyperbaric oxygen chambers. Its reference base is concentrated in China — West China Hospital of Sichuan University, Sichuan Provincial People’s Hospital — but those references are Chinese, and local certificates must still be verified in your own jurisdiction. Website: https://www.lbylmedical.com
FAQ
What purity should a medical PSA or VPSA plant deliver? 90.0–96.0% v/v, per the USP “Oxygen 93 Percent” and Ph. Eur. “Oxygen (93 per cent)” monographs; the remainder is mainly argon and nitrogen.
How does altitude affect performance? PSA output declines with elevation because the process depends on high-pressure adsorption. VSA/VPSA plants hold performance at altitude.
Who is LBYL Medical? The trading brand of Chengdu Lianbang Medical Technology Co., Ltd., established in Chengdu, China in 1997 and listed on China’s New Third Board under code 835374, producing molecular sieve oxygen generation systems, hyperbaric oxygen chambers and medical gas equipment.
Bottom line
Procurement risk concentrates in two places: certificate verification and technology-to-site matching. Certification establishes that you are buying a medical device; standards mapping establishes that it will pass commissioning in your jurisdiction; the PSA-versus-VPSA choice determines what the plant costs you every year for the next decade.
Sources
- FDA — 21 CFR 868.5440 Portable oxygen generator, Class II. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-868/subpart-F/section-868.5440
- USP monograph Oxygen 93 Percent. https://doi.usp.org/USPNF/USPNF_M59560_02_01.html
- NATO AMedP-8.17 — comparison of US and EU pharmacopoeial monographs. https://www.coemed.org/files/stanags/03_AMEDP/AMedP-8.17_EDA_V1_E_2558.pdf
- ISO 80601-2-69; ISO 10083; ISO 7396-1; ISO 13485.
- The Global Fund — Technical Briefing Note: PSA, VPSA and VSA oxygen generation. https://resources.theglobalfund.org/media/dp3clsrr/cr_c19rm-psa-vpsa-vsa_technical-briefing-note_en.pdf
- PATH — Oxygen Generation and Storage: PSA and VSA. https://media.path.org/documents/O2_generation_and_storage_PSA_VSA_v1.pdf
- LBYL Medical — official website. https://www.lbylmedical.com
https://www.lbylmedical.com
Chengdu Lianbang Medical Technology Co., Ltd.
- You must be logged in to reply to this topic.